Restoration of natural killer cell activity in chronic hepatitis C-infected Egyptian patients treated by sofosbuvir/daclatasvir with or without ribavirin
Background and aim Numerous studies demonstrate natural killer (NK) cell dysfunction in hepatitis C virus (HCV) infection. Direct-acting antivirals (DAAs) can change NK cell activation when HCV replication is inhibited. Only few studies have reported the effect of DAAs on NK cells, especially in gen...
Main Authors: | Hamdy M Moustafa, Muhammad Abdel-Gawad, Eman M Salaheldin, Nagat F.S Ibrahim |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2021-01-01
|
Series: | Al-Azhar Assiut Medical Journal |
Subjects: | |
Online Access: | http://www.azmj.eg.net/article.asp?issn=1687-1693;year=2021;volume=19;issue=1;spage=100;epage=106;aulast=Moustafa |
Similar Items
-
Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016-03-01) -
Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study
by: Rodolfo Sacco, et al.
Published: (2020-12-01) -
Treatment with Sofosbuvir and Daclatasvir (with or without Ribavirin) Improves Patient Reported Outcomes in Hepatitis C
by: Lucas Pereira Jorge de Medeiros, et al.
Published: (2018-04-01) -
Rapid Virological Response (RVR) of Daclatasvir and Sofosbuvir Plus Ribavirin in Non-Cirrhotic, Treatment-Naive Patients of Hepatitis C Virus Genotype 3
by: Muhammad Sarfraz, et al.
Published: (2018-12-01) -
Daclatasvir/Sofosbuvir versus Ledipasvir/Sofosbuvir in Patients with Hepatitis C Virus Infection Genotypes 1 and 3
by: Narjes Shokatpour, et al.
Published: (2020-06-01)